Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enterolactis Duo
- Development stage
- Unknown
- Lead developer
- Alfasigma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Enterolactis Duo is a synbiotic dietary supplement that combines the probiotic strain *Lacticaseibacillus paracasei* DG (formerly known as *Lactobacillus paracasei* DG) with the prebiotic fiber inulin. Developed by Sofar, it is designed to modulate the gut microbiota and support gastrointestinal health. Clinical evidence suggests that Enterolactis Duo can improve symptoms of functional constipation and irritable bowel syndrome (IBS). Furthermore, research into the brain-gut axis (BGA) has demonstrated its potential in ameliorating non-motor symptoms in patients with Parkinson's Disease, including improvements in cognitive and behavioral scores, as well as increasing the abundance of beneficial fecal bacteria such as *Faecalibacterium prausnitzii*.
- Brand names
- Enterolactis Duo
- Other names
- Lacticaseibacillus paracasei DG + inulinLactobacillus paracasei DG + inulin
Beyond the preview
Go deeper on Enterolactis Duo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enterolactis Duo.